08:48 AM EDT, 08/06/2026 (MT Newswires) -- Argenx's (ARGX.BR) subsidiary Avena Merger Sub launched a tender offer to acquire all issued and outstanding shares of US clinical-stage biopharmaceutical company Forte Biosciences for $77 per share in cash. Under the terms of a previously agreed merger plan, the immunology company's unit will merge with and into Forte, making the latter a wholly owned subsidiary of argenx, according to a Thursday release. The tender offer will expire on Aug. 26, unless extended or terminated early.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.